Vical (VICL) Upgraded to “Hold” by Zacks Investment Research
Vical (NASDAQ:VICL) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.
According to Zacks, “Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company’s DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. “
A number of other equities analysts also recently commented on VICL. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of Vical in a research note on Tuesday, November 21st. ValuEngine cut Vical from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $7.50.
Vical (NASDAQ:VICL) last issued its quarterly earnings data on Monday, October 23rd. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.02). The company had revenue of $3.24 million during the quarter, compared to analysts’ expectations of $3.60 million. Vical had a negative net margin of 92.13% and a negative return on equity of 29.06%. equities analysts expect that Vical will post -1 EPS for the current year.
In related news, Director Robert C. Merton acquired 85,700 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The shares were acquired at an average price of $1.75 per share, with a total value of $149,975.00. Following the completion of the purchase, the director now directly owns 95,451 shares in the company, valued at $167,039.25. The purchase was disclosed in a document filed with the SEC, which is available through this link. 5.88% of the stock is currently owned by corporate insiders.
A hedge fund recently raised its stake in Vical stock. New York State Common Retirement Fund raised its holdings in shares of Vical Incorporated (NASDAQ:VICL) by 83.6% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 130,706 shares of the biotechnology company’s stock after purchasing an additional 59,504 shares during the quarter. New York State Common Retirement Fund owned 1.18% of Vical worth $354,000 at the end of the most recent quarter. Institutional investors and hedge funds own 15.40% of the company’s stock.
WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/26/vical-vicl-upgraded-to-hold-by-zacks-investment-research.html.
Vical Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.